Chromosomal instability in cancer pathogenesis and treatment

A faulty copy machine in a cell’s nucleus—the BRCA2 gene—scrambles chromosomes when it breaks down, turning healthy breast or ovary cells into cancerous ones. This matters because women who inherit a broken BRCA2 gene face a drastically high risk of breast and ovarian cancers, yet doctors have lacked a clear picture of exactly how that single genetic glitch triggers the disease. The researchers have already discovered that BRCA2 directly protects chromosome structure and number during cell division. Now they will use lab-grown cells to map the precise molecular steps between a faulty BRCA2 gene and the birth of a cancer cell. If this fundamental science succeeds, it will not immediately change a patient’s daily life. But it will fill a critical gap: understanding the chain of events that turns a normal cell malignant. That knowledge could eventually allow doctors to predict which anti-cancer drugs will work best for women with inherited BRCA2 defects, moving beyond trial-and-error treatment. Similar fundamental discoveries about DNA repair mechanisms have already spawned targeted therapies like PARP inhibitors. This work could extend that logic to earlier, more precise interventions.